Arrestins in the Cardiovascular System - Progress in Molecular Biology and Translational Science - page 323

95. Lim GB. Vascular disease: no added benefit of niacin with statins. Nat Rev Cardiol .
2011;9:3.
96. Digby JE, Ruparelia N, Choudhury RP. Niacin in cardiovascular disease: recent pre-
clinical and clinical developments. Arterioscler Thromb Vasc Biol . 2012;32:582- 588.
97. Kather H, Aktories K, Schulz G, Jakobs KH. Islet-activating protein discriminates the
antilipolytic mechanism of insulin from that of other antilipolytic compounds. FEBS
Lett . 1983;161:149- 152.
98. Pike NB. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nic-
otinic acid. J Clin Invest . 2005;115:3400 - 3403.
99. Richman JG, Kanemitsu-Parks M, Gaidarov I, et al. Nicotinic acid receptor agonists
differentially activate downstream effectors. J Biol Chem . 2007;282:18028 - 18036.
100. Semple G, Skinner PJ, Gharbaoui T, et al. 3-(1H-tetrazol-5-yl)-1,4,5,6-
tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid recep-
tor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in
mice. J Med Chem . 2008;51:5101 - 5108.
101. Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb
Haemost . 2008;99:466 - 472.
102. Hardy AR, Conley PB, Luo J, Benovic JL, Poole AW, Mundell SJ. P2Y1 and P2Y12
receptors for ADP desensitize by distinct kinase-dependent mechanisms. Blood .
2005;105:3552- 3560.
103. Baurand A, Eckly A, Hechler B, et al. Differential regulation and relocalization of the
platelet P2Y receptors after activation: a way to avoid loss of hemostatic properties? Mol
Pharmacol . 2005;67:721- 733.
104. Soh UJ, Dores MR, Chen B, Trejo J. Signal transduction by protease-activated recep-
tors. Br J Pharmacol . 2010;160:191- 203.
105. Iwamoto R, Mekada E. ErbB and HB-EGF signaling in heart development and func-
tion. Cell Struct Funct . 2006;31:1 - 14.
106. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK. Beta-arrestins and cell signaling. Annu
Rev Physiol . 2007;69:483 - 510.
107. Esposito G, Perrino C, Cannavo A, et al. EGFR trans-activation by urotensin II recep-
tor is mediated by beta-arrestin recruitment and confers cardioprotection in pressure
overload-induced cardiac hypertrophy. Basic Res Cardiol . 2011;106:577- 589.
108. Zhai P, Galeotti J, Liu J, et al. An angiotensin II type 1 receptor mutant lacking epi-
dermal growth factor receptor transactivation does not induce angiotensin II-mediated
cardiac hypertrophy. Circ Res . 2006;99:528- 536.
109. Kim IM, Tilley DG, Chen J, et al. Beta-blockers alprenolol and carvedilol stimulate
betaarrestin-mediated EGFR transactivation. Proc Natl Acad Sci USA . 2008;105:
14555- 14560.
110. Tilley DG, Kim IM, Patel PA, Violin JD, Rockman HA. Beta-arrestin mediates beta1-
adrenergic receptor-epidermal growth factor receptor interaction and downstream sig-
naling. J Biol Chem . 2009;284:20375- 20386.
111. Smith NJ, Chan HW, Qian H, et al. Determination of the exact molecular require-
ments for type 1 angiotensin receptor epidermal growth factor receptor transactivation
and cardiomyocyte hypertrophy. Hypertension . 2011;57:973- 980.
112. Barki-Harrington L, Luttrell LM, Rockman HA. Dual inhibition of beta-adrenergic
and angiotensin II receptors by a single antagonist: a functional role for

receptor - receptor interaction in vivo. Circulation . 2003;108:1611- 1618.
113. Cervantes D, Crosby C, Xiang Y. Arrestin orchestrates crosstalk between G protein-
coupled receptors to modulate the spatiotemporal activation of ERK MAPK. Circ Res .
2010;106:79- 88.
114. Drake MT, Violin JD, Whalen EJ, Wisler JW, Shenoy SK, Lefkowitz RJ. b -Arrestin-
biased agonism at the b 2 -adrenergic receptor. J Biol Chem . 2008;283:5669- 5676.